(Q35039935)

5 August 2017

Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus (English)

1 reference

5 August 2017

Agnieszka Wierzbowska

series ordinal

2

object named as

Agnieszka Wierzbowska

1 reference

5 August 2017

6

Tadeusz Robak

1 reference

5 August 2017

1

Ewa Robak

1 reference

5 August 2017

3

Magdalena Chmiela

1 reference

5 August 2017

Liliana Kulczycka

4

1 reference

PubMed ID

16864898

5 August 2017

Anna Sysa-Jedrejowska

series ordinal

5

1 reference

PubMed ID

16864898

5 August 2017

language of work or name

1 reference

1 January 2006

1 reference

Mediators of Inflammation

5 August 2017

1 reference

5 August 2017

2006

1 reference

5 August 2017

1

1 reference

5 August 2017

17898

1 reference

Creative Commons Attribution 3.0 Unported

5 August 2017

start time

1 January 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

TIMPs as multifacial proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Metalloproteinase inhibitors: biological actions and therapeutic opportunities.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Matrix metalloproteinases: they're not just for matrix anymore!

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Current status of antiangiogenic factors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Systemic lupus erythematosus. Diagnosis and treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

The 1982 revised criteria for the classification of systemic lupus erythematosus

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Matrix metalloproteinases and their inhibitors in connective tissue remodeling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2FMI%2F2006%2F17898

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2FMI%2F2006%2F17898

Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1570389

Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus

9 December 2018

1 reference

12 December 2020

Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2

1 reference

12 December 2020

Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity

1 reference

12 December 2020

Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus

1 reference

12 December 2020

The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity

1 reference

12 December 2020

Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus

1 reference

12 December 2020

Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases

1 reference

12 December 2020

Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus

1 reference

12 December 2020

[Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus]

1 reference

12 December 2020

Systemic lupus erythematosus

1 reference

12 December 2020

Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma

1 reference

12 December 2020

Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity

1 reference

12 December 2020

Identifiers

DOI

10.1155/MI/2006/17898

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

PubMed ID

16864898